FDA approves new drug to treat multiple sclerosis
Food and Drug Administration, U.S. Department of Health and Human Services. (2017). FDA approves new drug to treat multiple sclerosis. Retrieved from https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm549325.htm.
On March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). This is the first drug approved by the FDA for PPMS. Ocrevus is an intravenous infusion given by a health care professional.
“Multiple sclerosis can have a profound impact on a person’s life,” said Billy Dunn, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “This therapy not only provides another treatment option for those with relapsing MS, but for the first time provides an approved therapy for those with primary progressive MS.”
PCOM Library / Hot Topics in Research / Internal Medicine / Neurology / Central Nervous System Disorders / Hot Topics: FDA Approves First Drug For Severe Multiple Sclerosis